ReviewCancer management and research2024

Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer.

Jiayun Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.